ombrabulin + docetaxel

**Ombrabulin + docetaxel** is a combination regimen used in investigational treatment of advanced solid tumors, notably explored for synergistic antitumor activity. *Ombrabulin* is a vascular disrupting agent (VDA) that induces rapid vascular shutdown in tumors, resulting in necrosis. It belongs to the combretastatin family and destabilizes tumor vasculature by targeting endothelial microtubules[1][4]. *Docetaxel* is a taxane-class chemotherapeutic that stabilizes microtubules, preventing cell division and causing cell cycle arrest[1]. Ombrabulin administration precedes docetaxel, typically by 24 hours, enabling enhanced anti-proliferative effects and observed additive or synergistic tumor cell kill. This regimen has been tested in phase I trials for a range of solid tumors, with recommended doses being ombrabulin 30–35 mg/m² followed by docetaxel 75–100 mg/m² intravenously every three weeks[1][3][4].

Other names

ombrabulin + docetaxel